IL156865A0 - D-amino acid oxidase and d-aspartate oxidase for use in cns disorders - Google Patents

D-amino acid oxidase and d-aspartate oxidase for use in cns disorders

Info

Publication number
IL156865A0
IL156865A0 IL15686502A IL15686502A IL156865A0 IL 156865 A0 IL156865 A0 IL 156865A0 IL 15686502 A IL15686502 A IL 15686502A IL 15686502 A IL15686502 A IL 15686502A IL 156865 A0 IL156865 A0 IL 156865A0
Authority
IL
Israel
Prior art keywords
oxidase
amino acid
cns disorders
aspartate
acid oxidase
Prior art date
Application number
IL15686502A
Other languages
English (en)
Original Assignee
Genset Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genset Sa filed Critical Genset Sa
Publication of IL156865A0 publication Critical patent/IL156865A0/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082Supracellular entities, e.g. tissue, organisms
    • G01N33/5088Supracellular entities, e.g. tissue, organisms of vertebrates
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/20Screening for compounds of potential therapeutic value cell-free systems
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/30Psychoses; Psychiatry
    • G01N2800/302Schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Psychology (AREA)
  • Toxicology (AREA)
IL15686502A 2001-01-16 2002-01-15 D-amino acid oxidase and d-aspartate oxidase for use in cns disorders IL156865A0 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US26188301P 2001-01-16 2001-01-16
US30544501P 2001-07-13 2001-07-13
US34521101P 2001-10-22 2001-10-22
US33388101P 2001-11-19 2001-11-19
PCT/IB2002/001262 WO2002066672A2 (en) 2001-01-16 2002-01-15 Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase antagonists

Publications (1)

Publication Number Publication Date
IL156865A0 true IL156865A0 (en) 2004-02-08

Family

ID=27500728

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15686502A IL156865A0 (en) 2001-01-16 2002-01-15 D-amino acid oxidase and d-aspartate oxidase for use in cns disorders

Country Status (11)

Country Link
EP (1) EP1412515A2 (xx)
JP (1) JP2004537275A (xx)
KR (1) KR20030066813A (xx)
CN (1) CN1568370A (xx)
AU (1) AU2002247939B2 (xx)
BR (1) BR0206495A (xx)
CA (1) CA2433866A1 (xx)
EA (1) EA006654B1 (xx)
IL (1) IL156865A0 (xx)
MX (1) MXPA03006321A (xx)
WO (1) WO2002066672A2 (xx)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE408593T1 (de) 2001-05-03 2008-10-15 Galileo Lab Inc Pyruvatderivate
EP1291015A1 (en) 2001-09-10 2003-03-12 Lunamed AG Dosage forms having prolonged active ingredient release
WO2003039540A2 (en) * 2001-11-09 2003-05-15 Sepracor Inc. D-amino acid oxidase inhibitors for learning and memory
WO2003047558A2 (en) * 2001-12-03 2003-06-12 Genset S.A. Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase inhibitors
US20060234221A1 (en) * 2001-12-12 2006-10-19 Genset S.A. Biallelic markers of d-amino acid oxidase and uses thereof
EP1495041A4 (en) * 2002-02-20 2006-02-01 Sirna Therapeutics Inc RNA interferon-mediated inhibition of gene expression of G72 and D-amino acid oxidase (DAAO) using short-term interfering nucleic acid (siNA)
GB0223424D0 (en) * 2002-10-09 2002-11-13 Imp College Innovations Ltd Disease-associated gene
BRPI0418244A (pt) 2003-12-29 2007-04-17 Sepracor Inc composto, métodos para aumentar a concentração de d-serina e/ou diminuir a concentração de produtos tóxicos da oxidação de d-serina pela daao em um mamìfero, para tratar a esquizofrenia, para tratar ou prevenir a perda de memória e/ou cognição associadas com o mal de alzheimer, para tratar a ataxia ou para prevenir a perda da função neuronal caracterìstica de doenças neurodegenerativas, para intensificar a aprendizagem, memória e/ou cognição e para tratar dor neuropática, e, composição farmacêutica
WO2007082208A2 (en) * 2006-01-09 2007-07-19 Oklahoma Medical Research Foundation Lanthionine-related compounds for the treatment of inflammatory diseases
US7884124B2 (en) 2006-06-30 2011-02-08 Sepracor Inc. Fluoro-substituted inhibitors of D-amino acid oxidase
US7902252B2 (en) * 2007-01-18 2011-03-08 Sepracor, Inc. Inhibitors of D-amino acid oxidase
GB2456390A (en) * 2008-01-15 2009-07-22 Glaxo Group Ltd Bipolar disorder treatments
US9649304B2 (en) 2009-01-20 2017-05-16 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical
JP4462382B1 (ja) * 2009-04-23 2010-05-12 学校法人北里研究所 D−アスパラギン酸オキシダーゼおよびd−アミノ酸オキシダーゼに対する新規阻害剤
WO2012135119A1 (en) * 2011-03-25 2012-10-04 Genomind, Llc Biomarker-based detection and treatment of neurodegenerative depression
EP2831232A4 (en) 2012-03-30 2015-11-04 Univ Washington METHODS OF MODULATING THE EXPRESSION OF TAU TO REDUCE THE STROKE AND MODIFY A NEURODEGENERATIVE SYMPTOM
RU2765625C2 (ru) 2016-06-13 2022-02-01 Сайньюрекс Интернэшнл (Тайвань) Корп. Сокристаллы бензоата лития и их применения
EP3468944B1 (en) 2016-06-13 2022-11-16 Syneurx International (Taiwan) Corp. Co-crystals of sodium benzoate and uses thereof
US10336679B2 (en) 2016-10-24 2019-07-02 Syneurx International (Taiwan) Corp. Polymorphic forms of sodium benzoate and uses thereof
US11369579B2 (en) 2016-10-24 2022-06-28 Syneurx International (Taiwan) Corp. Polymorphic forms of sodium benzoate and uses thereof
US10098861B1 (en) 2017-10-24 2018-10-16 Syneurx International (Taiwan) Corp. Pharmaceutical composition comprising sodium benzoate compound and clozapine, and uses thereof
CN108504752B (zh) * 2018-06-26 2021-05-11 华中农业大学 一种与母猪繁殖性状关联的分子标记及应用
CN111909907B (zh) * 2020-07-08 2022-05-24 浙江工业大学 天冬氨酸氧化酶突变体、工程菌及其在氧化-还原偶联制备精草铵膦中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5668117A (en) * 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
CA2361408A1 (en) * 1999-03-30 2000-10-05 Genset S.A. Schizophrenia associated genes, proteins and biallelic markers
AU6462500A (en) * 1999-07-29 2001-02-19 Patrick T. Prendergast Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement
WO2001068104A1 (en) * 2000-03-16 2001-09-20 The Mclean Hospital Corporation Compounds for the treatment of psychiatric or substance abuse disorders

Also Published As

Publication number Publication date
AU2002247939B2 (en) 2007-01-25
MXPA03006321A (es) 2003-10-06
BR0206495A (pt) 2006-01-24
CN1568370A (zh) 2005-01-19
WO2002066672A3 (en) 2004-02-26
JP2004537275A (ja) 2004-12-16
CA2433866A1 (en) 2002-08-29
KR20030066813A (ko) 2003-08-09
EA200300807A1 (ru) 2004-08-26
EA006654B1 (ru) 2006-02-24
AU2002247939B9 (en) 2002-09-04
EP1412515A2 (en) 2004-04-28
WO2002066672A2 (en) 2002-08-29

Similar Documents

Publication Publication Date Title
IL156865A0 (en) D-amino acid oxidase and d-aspartate oxidase for use in cns disorders
EP1423120A4 (en) 2H-PHTALAZINE-1-ONES AND METHODS OF USE THEREOF
SG114523A1 (en) Polishing composition and polishing method employing it
GB2383962B (en) Catalytic composition and use therefor
AU2001288249A1 (en) Biosensors and methods for their use
SG85153A1 (en) Polishing composition and polishing process
AU2002339696A8 (en) Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase inhibitors
EP1416276A4 (en) BIOSENSORS AND MEASURING PROCEDURES
AU2001249969A1 (en) Inha inhibitors and their use as antibacterials
ZA200306171B (en) (Diazolo-pyridinyl)-pyrimidines for use in treatment of CNS disorders and diabetes.
SG94358A1 (en) Polishing composition and method
EP1419905A4 (en) WINTER TIRES
AU2003255993A1 (en) Diazabicyclic compounds useful in the treatment of cns and other disorders
SG99407A1 (en) Polishisng composition and polishing method employing it
AU2003238702A8 (en) Method for utilizing the 5'end of mrna for cloning and analysis
GB0126643D0 (en) Composition and process
IL161741A0 (en) Methods of reversing and preventingcardiovascular pathologies
AU2001271400A1 (en) Bioelastomer nanomachines and biosensors
EP1406720A4 (en) BUFFERS FOR ELECTROPHORESIS AND USE THEREOF
IL153276A0 (en) Metalloprotease peptide substrates and methods
GB0109091D0 (en) Hypertension treatment and assay
EP1367123A4 (en) NEUROTONIN AND ITS USE
AU2002304725A1 (en) Transformation of (di)amines in the presence of a lysine oxidase and a reducing agent
HUP0402141A3 (en) Herbicidal composition and process for its use
TW483383U (en) Buckling and holding wrench